贝利尤单抗联合利妥昔单抗治疗原发性膜性肾病
REBOOT A 研究为单臂开放标签药代动力学研究,纳入17例蛋白尿≥4 g/d且抗PLA2R抗体阳性的原发性膜性肾病患者,接受贝利尤单抗200 mg皮下每周一次共52周,联合利妥昔单抗1000 mg静脉输注于第4、6周。第104周时,全部治疗参与者中10/17(59%)达到完全或部分缓解,符合方案分析中10/11(91%)达到缓解;联合治疗耐受良好,1例因感染停用贝利尤单抗。
要点
- 贝利尤单抗联合利妥昔单抗可使部分原发性膜性肾病患者达到完全或部分缓解。
- 高蛋白尿(≥8 g/d)未显著降低第4周贝利尤单抗暴露。
- 联合治疗总体耐受良好,仅1例因感染停用贝利尤单抗。
核心结论
- 贝利尤单抗联合利妥昔单抗治疗原发性膜性肾病,较高比例参与者达到完全或部分缓解。
研究设计与样本
- REBOOT Part A(NCT03949855)为单臂、开放标签、药代动力学研究,共17例参与者开始贝利尤单抗治疗。
主要发现
- 全部治疗参与者中10/17(59%)在第104周达到完全或部分缓解,符合方案分析中10/11(91%)达到缓解。
- 符合方案分析的所有参与者第104周血清白蛋白正常且血清抗PLA2R抗体检测不到。
- 循环记忆B细胞在利妥昔单抗前升高,并被利妥昔单抗清除;第52周后B细胞重建,以初始和过渡型B细胞为主。
关键数值与推荐
- 参与者蛋白尿≥4 g/d且血清抗PLA2R抗体可检测。
- 贝利尤单抗200 mg皮下每周一次共52周,利妥昔单抗1000 mg静脉输注于第4、6周。
- 高蛋白尿(≥8 g/d)者第4周贝利尤单抗暴露未显著降低。
- 1例参与者因感染停用贝利尤单抗。
临床怎么用
- 对于蛋白尿≥4 g/d且抗PLA2R抗体阳性的原发性膜性肾病患者,贝利尤单抗联合利妥昔单抗的多靶点B细胞清除策略可能改善免疫学和临床结局。
局限性
- 本研究为单臂、开放标签、小样本药代动力学研究,结果需更大规模随机安慰剂对照试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: B cell depletion with rituximab (RTX) leads to complete or partial remission (CR or PR) in approximately 60% of patients with primary membranous nephropathy (PMN). Adding belimumab (BEL) to RTX may result in greater depletion of memory B cells, limit the reemergence of autoreactive B cells, and improve clinical responses. METHODS: REBOOT Part A (NCT03949855) is a single arm, open-label, pharmacokinetic study where all participants had proteinuria (≥ 4 g/d) and detectable serum anti-phospholipase A2 receptor (anti-PLA2R) antibodies. Participants received BEL 200 mg subcutaneously weekly for 52 weeks and RTX 1000 mg intravenously at weeks 4 and 6. Assessments included BEL exposure at week 4 and CR or PR at week 104. RESULTS: A total of 17 participants started BEL. BEL exposure was not significantly reduced in those with high proteinuria (≥8 g/day) at week 4. Among all treated participants, 10/17 (59%) achieved CR or PR at week 104, whereas in per protocol analyses, 10/11 (91%) achieved CR or PR at week 104. All participants in per protocol analyses had normal serum albumin and undetectable serum anti-PLA2R by week 104. Circulating memory B cells increased before RTX and were depleted by RTX. B cell reconstitution occurred after week 52 with primarily naive and transitional B cells. BEL with RTX was well-tolerated, with 1 participant discontinuing BEL due to infection. CONCLUSION: In this study, a high proportion of participants receiving BEL with RTX achieved CR or PR. Therefore, a multitargeted approach to B cell depletion may improve immunologic and clinical outcomes in PMN and is being studied in a larger, randomized, placebo-controlled clinical trial.
引用
- Chung SA, Stelzig L, Sherman MA, et al. Belimumab With Rituximab for the Treatment of Primary Membranous Nephropathy. Kidney Int Rep. 2026. PMID: 42926931. doi:10.1016/j.ekir.2026.107075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。